Vol 15, No 2 (2019)

Date published: 2019-05-17

Table of Contents

open access

ORIGINAL ARTICLE

Consistency in biomarkers expression between matched tissue microarray cores from primary gallblader and ovarian cancers

Beata Hryciuk, Bartosz Szymanowski, Michał Bieńkowski, Adrian Perdyan, Aleksandra Korwat, Kamil Winnik, Barbara Radecka, Jolanta Żok, Natalia Cichowska, Katarzyna Sosińska-Mielcarek, Rafał Pęksa, Renata Duchnowska

DOI: 10.5603/OCP.2019.0011
Oncol Clin Pract 2019;15(2):85-88.
REVIEW ARTICLES

Critical appraisal of clinical trials in oncology — part I

Marcin Kaczor, Rafał Wójcik, Joanna Połowinczak-Przybyłek, Piotr Potemski

DOI: 10.5603/OCP.2018.0057
Oncol Clin Pract 2019;15(2):89-103.

Benefits and difficulties during brain radiotherapy planning with hippocampus sparing

Monika Konopka-Filippow, Ewa Sierko, Marek Z. Wojtukiewicz

DOI: 10.5603/OCP.2019.0019
Oncol Clin Pract 2019;15(2):104-110.

Neratinib in adjuvant treatment of patients with HER2-positive breast cancer — less is more?

Ewa Cedrych, Ida Cedrych

DOI: 10.5603/OCP.2019.0014
Oncol Clin Pract 2019;15(2):111-114.

Why do we need a new BRAF-MEK inhibitor combination in melanoma?

Katarzyna Kozak, Piotr Rutkowski

DOI: 10.5603/OCP.2018.0054
Oncol Clin Pract 2019;15(2):115-119.
CASE REPORT

The effectiveness of chemotherapy in small cell lung cancer patients with BRCA2 gene mutation and Schwartz-Bartter syndrome

Małgorzata Flis, Paweł Krawczyk, Izabella Drogoń, Katarzyna Kurek, Robert Kieszko, Janusz Milanowski

DOI: 10.5603/OCP.2019.0008
Oncol Clin Pract 2019;15(2):120-123.

Nivolumab in the treatment of advanced renal cell carcinoma

Piotr Tomczak, Zuzanna Synowiec

DOI: 10.5603/OCP.2018.0040
Oncol Clin Pract 2019;15(2):124-126.

Complete pathological remission after palliative therapy with sorafenib in hepatocellular carcinoma — case report

Aneta Lebiedzińska, Dawid Sigorski, Maciej Michalak, Zygmunt Kozielec, Anna Doboszyńska, Dariusz Zadrożny, Paweł Różanowski

DOI: 10.5603/OCP.2019.0010
Oncol Clin Pract 2019;15(2):127-131.

When to say “no” to a patient with an ovarian tumour and in poor general condition?

Kamila Kaźmierczak, Joanna Kufel-Grabowska, Tomasz Kozłowski, Błażej Nowakowski

DOI: 10.5603/OCP.2019.0018
Oncol Clin Pract 2019;15(2):132-134.
CURRENT LITERATURE REVIEW

Current literature review

Maciej Kawecki

Oncol Clin Pract 2019;15(2):135.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl